This article is more than 5 years old. Information may no longer be current.

FDA accepts NDA for Rhopressa

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

The FDA has accepted a new drug application for Rhopressa and set a PDUFA goal date of Feb. 28, 2018, according to a press release from Aerie Pharmaceuticals.

Rhopressa (netarsudil ophthalmic solution 0.02%) is a once-daily eye drop designed to lower IOP by targeting the trabecular meshwork.

“We are obviously delighted with this positive news on our Rhopressa NDA. The February 28, 2018, PDUFA date and the advisory committee plans are consistent with our previously disclosed expectations,” Vicente Anido Jr., PhD, chairman and CEO of Aerie, said in the release.